USTR opens section 301 investigation into Germany’s drug‑pricing reforms

The United States has launched a formal trade investigation into Germany’s proposed drug‑spending reforms, escalating concerns that the country’s pricing policies may undervalue innovative medicines and disadvantage US pharmaceutical companies.

The Office of the United States Trade Representative (USTR) announced the Section 301 probe last week, saying it